Selective NOX2 Inhibitor Compound for Inflammatory and Fibrotic Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for NADPH oxidase 2 (NOX2)-related diseases, such as inflammatory and fibrotic diseases, lack effective inhibitors, limiting therapeutic options.
Innovation Solution
Development of a novel compound represented by Chemical Formula 1 or its isomers and pharmaceutically acceptable salts, which selectively inhibit NADPH oxidase 2 (NOX2), offering potential therapeutic agents for these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for NOX2-related diseases, then existing therapeutic options are limited, but no effective inhibitors are available
Solution Approach 1:
The patent segments the broad category of NOX enzymes into specific isoforms, particularly targeting NOX2 with compound 1. This selective inhibition approach allows the compound to address specific disease mechanisms mediated by NOX2 without affecting other NOX isoforms, thereby providing reliable therapeutic effectiveness for NOX2-related diseases while maintaining specificity.
Solution Approach 2:
The patent introduces compound 1 with specific molecular parameters (chemical structure, binding affinity, selectivity) that differ from existing inhibitors. By optimizing these parameters, the compound achieves effective inhibition of NOX2 with improved therapeutic profile, expanding the available therapeutic options for inflammatory and fibrotic diseases.
2Adaptability or versatility
If NOX2 inhibitors are developed as first-in-class drugs, then new therapeutic agents can be provided, but none have been successfully developed yet
Solution Approach 1:
Compound 1 is designed with universal applicability across multiple NOX2-related disease conditions including inflammatory diseases, fibrotic diseases, and neurodegenerative diseases. The compound's mechanism of selectively inhibiting NOX2 makes it a versatile therapeutic agent that can address various pathologies driven by ROS production, expanding therapeutic applications while maintaining a unified mechanism of action.
Solution Approach 2:
The patent positions compound 1 as an intermediary substance that mediates the inhibition between NOX2 and its downstream effects (ROS production, inflammation, fibrosis). By targeting the enzyme-substrate interaction at the molecular level, the compound effectively interrupts the pathological cascade without directly affecting the complex disease processes, thereby improving clinical success probability.
3Measurement precision
If selective NOX2 inhibition is achieved, then specific disease mechanisms can be targeted, but inhibitor development has not yet succeeded
Solution Approach 1:
Compound 1 exhibits local quality in its selective interaction with NOX2, demonstrating high binding affinity and specificity for this particular enzyme isoform while showing minimal activity against other NOX family members. This localized specificity at the molecular recognition level enables precise targeting of NOX2-mediated pathways without off-target effects, achieving measurement precision in target selection.
Solution Approach 2:
The patent employs compound 1 as a composite molecular structure combining specific pharmacophoric elements that collectively achieve selective NOX2 inhibition. The composite nature of the molecule, with its specific functional groups and spatial arrangement, enables both high target specificity and favorable pharmacological properties, addressing the challenge of inhibitor development.
Data Source
AI summary
The present invention relates to a novel compound as an NADPH oxidase 2 inhibitor and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits selective and excellent inhibitory activity against NADPH oxidase 2, which is known to date, and thus can be advantageously used as a therapeutic for various diseases associated with NADPH oxidase 2, such as inflammatory diseases, fibrotic diseases, and degenerative neural diseases.